Merck Suggests More IO/ADC Combos To Come Under Oncology Strategy
The company laid out a three-pronged strategy focused on immuno-oncology, antibody-drug conjugates as well as small molecules, with four programs set to enter pivotal trials this year.
You may also be interested in...
Keytruda and Gardasil lead Merck’s growth story, although Lagevrio’s ongoing decline placed a drag on quarterly performance. Lung cancer is driving Keytruda’s momentum outside the US.
Coming less than three months before the statutory deadline for CMS to publish the initial list of drugs, Merck’s lawsuit calls US Medicare drug price negotiations ‘extortion’ in a complaint that could be the first of more legal pushback to follow.
In Trop2 Merck & Co. might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.